Newsroom | 49100 results

ALLSTON, Mass.--(BUSINESS WIRE)--Nia Therapeutics announced publication in Brain Stimulation of the first in vivo validation of its Smart Neurostimulation System (SNS), a wireless, implantable brain-computer interface designed for closed-loop treatment of memory disorders. The SNS records neural activity from 60 channels across four brain regions—an order-of-magnitude increase over commercially available devices. The NeuroPace RNS system, FDA-cleared for epilepsy, records from up to six channel...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company’s common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare in...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming...

DUBLIN--(BUSINESS WIRE)--The "Europe Image-Guided Drug Delivery Market: Focus on Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Europe image-guided drug delivery market is projected to reach $284.1 million by 2035 from $13.7 million in 2024, growing at a CAGR of 32.01% during the forecast period 2025-2035. The growing use of IGDD systems throughout Europe and developments in sophist...

DUBLIN--(BUSINESS WIRE)--The "Bipolar Disorder: Opportunity Assessment and Forecast" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the Bipolar Disorder market through 2034. The bipolar disorder market is crowded with inexpensive generic products and off-label drugs. There are currently not many effective treatments targeting bipolar depression, warranting targeted drug development. In the late-stage pipeline...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Dec. 31, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 10 individuals hired by Sarepta in the fourth quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule...

DUBLIN--(BUSINESS WIRE)--The "Spondyloarthritis (Spondyloarthropathy) - Global Clinical Trials Review, 2025" clinical trials report has been added to ResearchAndMarkets.com's offering. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for i...

DUBLIN--(BUSINESS WIRE)--The "Lupus Nephritis - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on num...

DUBLIN--(BUSINESS WIRE)--The "IgA Nephropathy (Berger's Disease) - Global Clinical Trials Review, 2025" clinical trials report has been added to ResearchAndMarkets.com's offering. This report provides top line data relating to the clinical trials on IgA Nephropathy (Berger's Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), ph...

TORONTO--(BUSINESS WIRE)--New data from Phoenix found 38% of Canadians don’t consider their health and wellness goals to be enough of a reason to book a doctor’s appointment....